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ABSTRACT 
Background: The extent of hyperkalemia among Thai heart failure patients taking angiotensin-converting enzyme inhibitor 
(ACEI) has not been well understood.  
Objective: This retrospective descriptive study aimed to explore the rate and severity of hyperkalemia in heart failure patients 
taking ACEI alone or in combination with spironolactone.  
Methods: Heart failure patients visiting the outpatient department of Chiangrai Regional Hospital during 2001 - 2005 were 
included. Patients must have hyperkalemia during study period and used enalapril, an only ACEI available in this hospital. 
Frequency and severity of hyperkalemia associating with medication regimens, chronic kidney disease (CKD), medications used 
in addition to enalapril, as well as mean levels of potassium and onset of hyperkalemia were examined.  
Results: Twenty eight patients were included in analysis. Most patients were the elderly (average age of 70.54 years). The 
most frequently found co-morbid diseases were chronic kidney disease, diabetes mellitus and hypertension. About 57.14% of 
the patients took enalapril alone. In addition to enalapril, the medications most frequently taken were furosemide (71.43%), 
followed by NSAIDs (50.0%), and spironolactone (42.86%). The onset of hyperkalemia was mostly within 3 months. Most 
hyperkalemia episodes were mild (53.57%). Patients with a higher likelihood to experience a more severe hyperkalemia included 
those who used enalapril combined with either spironolactone or amiloride and those with CKD.   
Conclusion: Although ACC/AHA 2005 Chronic Heart Failure guideline update recommended ACEIs and spironolactone in stage 
C heart failure patients, both the two medications might induce hyperkalemia. To prevent medication-induced hyperkalemia, 
practitioners should therefore regularly monitor blood potassium level in these patients, particularly those receiving the 
combination therapy and those with CKD.  
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Introduction
§ACC/AHA 2005 Chronic Heart Failure guideline 
update advised that heart failure patients should receive 
angiotensin converting enzyme inhibitors (ACEIs), beta-
                                                        
§
 13th year of Srinakharinwirot Journal of Pharmaceutical Science 
blockers and spironolactone.
1
 Since heart failure (HF) 
stimulates sympathetic nervous system and renin-
angiotensin-aldosterone system, this increasing aldos-
terone further results in myocardial fibrosis, adverse 
vascular remodeling, collagen synthesis and endothelial 
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dysfunction.
2
 Randomized Aldactone Evaluation Study 
(RALES) indicated that spironolactone reduced morbidity 
and mortality rate in systolic dysfunction heart failure 
patients.
3
 Since the release of RALES in 1999, the use 
of spironolactone has been increasing to 18.5%.
4
  
Despite the benefit of spironolactone, the use of 
spironolactone with ACEIs in heart failure patients is 
associated with hyperkalemia. An incidence of overall 
hyperkalemia among these patients was 15 - 33%, while 
severe hyperkalemia, a blood potassium level of more 
than 6 mEq/L, was 6 - 14%.
5,6
 On the contrary, the use 
of enalapril was associated with a lower incidence of 
hyperkalemia, only 2%.
5
 It was found that hyperkalemia 
occurred within 15 ± 9 days among patients taking 
enalapril, and slightly faster among those taking  
enalapril concomitantly with spironolactone (11 ± 6 
days).
5
 Hyperkalemia associated with the use of ACEIs 
was described in a few studies where the incidence of 
hyperkalemia was approximately 11 - 15% and severe 
hyperkalemia was about 1.5 - 3%.
7,8
  
The likelihood of hyperkalemia in heart failure patients 
receiving ACEIs and spironolactone was increased by 
various exaggerating factors including renal insufficiency, 
older age, the use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) and beta-blockers. Shah and colleagues 
estimated that the incidence of hyperkalemia among 
heart failure patients with a serum creatinine of 1.5 
mg/dL who used ACEIs and spironolactone was 
considerably high (35%), and even higher (63%) among 
those with an increased serum creatinine of 2.5 mg/dL.
6 
  
The incidence of hyperkalemia associated with the use 
of ACEIs in actual practice in Thailand has not been 
studied. The extent and severity of the problem could 
potentially raise safety concerns among practitioners and 
hopefully result in drug safety among Thai patients. Our 
exploratory study aimed to describe clinical character-
ristics of heart failure patients taking enalapril who 
experienced hyperkalemia. This retrospective analysis 
was conducted at Chiangrai Regional Hospital. Results 
from the study could help suggest a better practice to 
prevent medication-induced hyperkalemia in heart failure 
patients.  
Methods 
In this retrospective descriptive study, outpatient 
medical records at Chiangrai Regional Hospital were 
searched for patients diagnosed with heart failure. Heart 
failure patients visiting OPD department between 2001 & 
2005 were further validated for hyperkalemia episode. In 
this study, different levels of hyperkalemia were defined 
as follows: hyperkalemia as a blood potassium level of 
5.5 mEq/L or higher, mild hyperkalemia as a level 
between 5.5 to 6.4 mEq/L, moderate hyperkalemia as a 
level between 6.5 and 7.5 mEq/L, and severe 
hyperkalemia as a level of more than 7.5 mEq/L. 
Heart failure patients with any level of hyperkalemia 
were included in the study. These patients must have 
had receiving enalapril, the only ACEI available in this 
hospital, and blood potassium level monitored at least 
once during 2001 to 2005. Patients who did not receive 
continuous medical service at this hospital were 
excluded. Demographic and clinical status data were 
extracted from outpatient medical records. These 
information included age, gender, past medical history, 
medication history, and blood potassium level. Possibility 
of medication induced hyperkalemia was evaluated by 
using NaranjoEs algorithm.  
By means of descriptive statistics, we examined 
frequency of hyperkalemia with various severity levels in 
relation to different types of medications, and the 
presence of chronic kidney disease. Onset of 
hyperkalemia associating with enalapril and/or 
spironolactone was identified. Mean blood potassium 
level among patients with and without chronic disease, 
and among those with and without use of spironolactone 
or furosemide in addition to enalapril were also 
presented.  
 
Results 
Fifty six patients had heart failure with hyperkalemia. 
However only 28 of them took enalapril and therefore 
were included in analysis. Among these 28 patients, 
most of them were the elderly with an average age of 
70.54 ± 10.62 years (range 44 - 87) (Table 1). Proportion 
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of gender was considerably equal. Regarding medical 
history, the most frequently found co-morbid diseases 
were chronic kidney disease, diabetes mellitus and 
hypertension (46.42%, 42.86% and 39.29%, respect-
tively). More than half of the patients took enalapril alone 
(57.14%). In addition to enalapril, the medication most 
frequently taken by the patients was furosemide 
(71.43%), the drug which could potentially cause 
potassium loss, followed by NSAIDs (50.0%), and 
spironolactone (42.86%). Both digoxin and beta-
adrenergic antagonists were taken by about one third of 
the patients (35.71% and 32.14% respectively). The 
combination use of amiloride and hydrochlorothiazide 
(HCTZ) was found only in 2 patients.   
More than half of the patients took enalapril with a 
dose of 10 mg/day or higher (57.14%) (Table 1). The 
guideline recommends that heart failure patients should 
receive 12.5 - 25 mg per day of spironolactone and most 
patients in this study (11 patients) took these doses. 
However, one patient who had cirrhosis received a 100 
mg/day of spironolactone.  
Among 28 heart failure patients with hyperkalemia and 
receiving enalapril, possibility of enalapril-caused 
hyperkalemia as evaluated by using NaranjoEs algorithm 
was in HpossibleI level in most patients (19 out of 28 
patients). Regarding severity of hyperkalemia, these 
hyperkalemia episodes were defined as HmildI in most 
patients (53.57%) (Table 2). Moderate hyperkalemia was 
found less frequent (28.57%) and severe hyperkalemia 
was found the least (17.86%). In terms of frequency of 
incidence of hyperkalemia, most patients experienced 
hyperkalemia only once a year (22 patients or 78.57%). 
Fewer patients experienced the event twice a year (5 
patients or 17.86%) and only one patient who also had 
chronic kidney disease experienced hyperkalemia 3 
times in one year.  
 
 
 
 
 
Table 1 Demographic and clinical characteristics of the 
patients (N = 28).  
Frequency of 
patients Demographic and clinical data 
Number % 
Gender   
Male 15 53.60 
Female 13 46.42 
Past medical history*   
Chronic kidney disease 13 46.42 
Diabetes mellitus 12 42.86 
Hypertension 11 39.29 
Ischemic heart disease 9 32.14 
COPD 8 28.37 
Gout 4 14.29 
Cirrhosis 4 14.29 
Dyslipidemia 2 7.14 
Myocardial infarction 2 7.14 
Medications
#
     
Enalapril alone 16 57.14 
Furosemide 20 71.43 
Nonsteroidal anti-inflammatory drugs 14 50.00 
Spironolactone 12 42.86 
Digoxin  10 35.71 
Beta-adrenergic antagonists 9 32.14 
Aspirin 6 21.43 
Amiloride and hydrochlorothiazide 2 7.14 
Angiotensin receptor blockers 1 3.57 
Dose of enalapril (mg/day)   
5  12 42.86 
10  5 17.85 
> 10  11 39.29 
* One patient may have more than one co-morbid disease.  
#
 One patient may use more than one kind of medication.  
 
 
Table 2 Number of patients with different hyperkalemia 
severities.   
Frequency of patients Severity of 
hyperkalemia 
Blood K level  
(mEq/L) Number 
(N = 28) 
% 
Mild  > 5.5 & 6.4 15 53.57 
Moderate  6.5 - 7.5 8 28.57 
Severe  > 7.5 5 17.86 
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In terms of onset of medication-induced hyperkalemia, 
only 14 of 28 patients (50%) had complete data from 
OPD chart concerning duration of the use of enalapril or 
combined enalapril and spironolactone (Table 3). Of 
these 14 patients, 9 was found experiencing 
hyperkalemia within 3 months after treatment. It was also 
found that 4 patients experiencing hyperkalemia after 9 
months to 4 years of the therapy were all patients with 
chronic kidney disease.  
 
 
Table 3 Number of patients with different onsets of 
hyperkalemia induced by enalapril or enalapril 
plus spironolactone.  
Onset 
Number of patients 
(N = 14)  
0 - 3 months 9 
4 - 6 months 1 
6 - 9 months 0 
9 months & 1 year 2 
1 - 4 years 2 
 
 
Most patients taking enalapril alone had mild 
hyperkalemia (9 patients or 56.25%) somewhat similar to 
those receiving enalapril and spironolactone (6 patients 
or 50%) (Fig. 1). Moderate and severe hyperkalemia was 
found in almost half of the patients using both 
medications. The patients receiving enalapril and 
spironolactone were more likely to experience a more 
severe hyperkalemia (50%) (33.33% with moderate 
hyperkalemia and 16.67% with severe hyperkalemia) 
than those taking enalapril alone (43.75%). 
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Figure 1 Frequency of patients experiencing hyperkal-
emia by type of therapy (enalapril alone or 
combination of enalapril and spironolactone).  
 
 
Hyperkalemia among patients with chronic kidney 
disease  
When co-morbidity of chronic kidney disease (CKD) 
was considered, it was found that patients with CKD 
were more likely to have a more severe hyperkalemia 
(Table 4). This was evident as 30.7% of them had 
moderate hyperkalemia and 23.2% had severe one while 
the rest (46.1%) experienced mild hyperkalemia. On the 
contrary, hyperkalemia the patients with no CKD 
experienced were more likely to be mild in nature 
(60.0%), and much fewer patients with moderate and 
severe hyperkalemia (26.7% and 13.3% respectively).  
 
 
Table 4 Frequency of patients with and without chronic 
kidney disease who experienced hyperkalemia 
with different severities.   
Severity of hyperkalemia CKD  
co-morbidity Mild Moderate Severe 
Total 
With CHD 6 
(46.1%) 
4 
(30.7%) 
3 
(23.2%) 
13 
(100%) 
Without CKD 9 
(60.0%) 
4 
(26.7%) 
2 
(13.3%) 
15 
(100%) 
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Among 13 patients with chronic kidney disease, 8 of 
them took enalapril alone while the rest (5 patients) took 
enalapril and spironolactone. Half of those taking 
enalapril alone (4 out of 8) experienced mild hyper-
kalemia; while 3 out of 5 patients (60.0%) taking enalapril 
and spironolactone experienced ones with moderate to 
severe levels (Table 5). This was supporting the concept 
that enalapril alone could cause mostly mild 
hyperkalemia.  
 
Table 5 Frequency of patients with chronic kidney 
disease experiencing hyperkalemia by type of 
theapy (enalapril alone or combination of 
enalapril and spironolactone). 
Severity of hyperkalemia Medications 
Mild Moderate Severe 
Total 
Enalapril  4 
(50.0%) 
2 
(25.0%) 
2 
(25.0%) 
8 
(100%) 
Enalapril +  
spironolactone 
2 
(40.0%) 
2 
(40.0%) 
1 
(20.0%) 
5 
(100%) 
 
Hyperkalemia associated with medications used 
in addition to enalapril  
Proportions of moderate and severe hyperkalemia 
among patients taking enalapril with spironolactone or 
amiloride (50.0%) were higher than those taking enalapril 
with NSAIDs (25.0%) or with beta-blockers (22.2%) 
(Table 6). This was interesting since proportions of 
patients who took enalapril with NSAIDs or with beta-
blockers were higher than those taking enalapril with 
either spironolactone or amiloride (Table 1).  
 
Table 6 Frequency of patients experiencing hyperkal-
emia by different medications used in addition 
to enalapril.  
Severity of hyperkalemia Medications 
Mild Moderate Severe 
Total 
Spirinolactone / 
amiloride 
6 
(50.0%) 
4 
(35.7%) 
2 
(14.3%) 
12 
(100%) 
NSAID including 
aspirin 
15 
(75.0%) 
4 
(20.0%) 
2 
(5.0%) 
20 
(100%) 
Beta-blocker 7 
(77.8%) 
1 
(11.1%) 
1 
(11.1%) 
9 
(100%) 
Average blood potassium in various types of 
patients  
Patients with chronic kidney disease and patients 
taking spironolactone in addition to enalapril had mean 
blood potassium level higher than their counterparts 
(Table 7). As expected, the use of furosemide in addition 
to enalapril resulted in a lower mean blood potassium 
level than that associating with using enalapril alone.  
 
Table 7 Mean blood potassium level.  
Subgroups of patients 
Mean blood K level 
(mEq/L)  
Patients with chronic kidney disease   
Yes (n = 13) 6.51 
No (n = 15) 6.22 
Spironolactone in addition to enalapril  
Yes (n = 12) 6.49 
No (n = 16) 6.25 
Furosemide in addition to enalapril   
Yes (n = 20) 6.20 
No (n = 8) 6.41 
 
Discussions 
Among heart failure patients with hyperkalemia, about 
50% used enalapril and half of these patients had mild 
hyperkalemia (53.57%). Higher severity of hyperkalemia 
(moderate to severe) was more likely to associate with 
having chronic kidney disease and taking spironolactone. 
Most enalapril-induced hyperkalemia episodes occurred 
within a short period of time (0 - 3 months) after taking 
enalapril. This finding was in accordance with a study by 
Cruz et al. which indicated an average of 11 ± 6 days of 
the onset.
5
 In our study, the exact onset of hyperkalemia 
was unable to obtain since most patients were not 
monitored for blood potassium level as frequently as 
every 2 weeks to every 1 month as found in other 
studies. On the other hand, patients in our studies were 
monitored for blood potassium whenever hyperkalemia 
was suspected by the physician. This kind of actual 
practice could be responsible for a longer onset of 
detected hyperkalemia in this study.  
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The delayed onset of enalapril induced hyperkalemia 
was found but the chance of such event was less likely. 
This is because 4 patients who experienced hyper-
kalemia during 9 months to 4 years were those with 
chronic kidney disease as an underlying disease. The 
delayed onset of hyperkalemia was less likely to be 
attributable to enalapril, but merely to the underlying 
disease itself.  
Other limitation in our study may include retrospective 
data collection which may have missed various clinical 
information. More importantly, level of potassium intake 
from the patient regular diet was unable to estimate. 
Further prospective study with a more complete data 
collection could help obtain a clearer picture of 
hyperkalemia in heart failure patients using angiotensin-
converting enzyme inhibitors.  
Even with some limitations, the results of this study 
along with the existing clinical guidelines on preventing 
ACEI-induced hyperkalemia
6,11
 could suggest that the 
following cautions should be exercised when an ACEI is 
used in heart failure patients. 1) The patients should be 
examined for blood potassium level before they receive 
the medication. 2) For patients with high risk for 
hyperkalemia or with existing high potassium level, blood 
potassium level should be monitored within 2 weeks after 
the drug is added and every 2 months thereafter. These 
high-risk patients may include those with chronic kidney 
disease and those receiving enalapril and spironolactone. 
3) For patients who are a candidate for ACEI and had a 
creatinine clearance (CrCl) of 30 - 60 mL/min/1.73 m
2
, 
they should be monitored regularly for blood potassium 
level, especially those who had a CrCl of less than 30 
mL/min/1.73 m
2
. 4) For patients with low risk for 
hyperkalemia, after ACEI initiation, blood potassium level 
should be monitored every 1 to 3 months. 5) For all 
patients, the use of unnecessary medications with a 
potential to cause hyperkalemia, for example NSAIDs 
both conventional ones and cycloxygenase-2 inhibitors, 
should be avoided.  
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